Drug Trial Radar · NCT07939594
An Evaluation of the Potential for VH4011499 Drug-drug-interactions
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Nov 16, 2026
Primary completion
Mar 12, 2027
Study completion Mar 12, 2027
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the pharmacokinetic (PK) interactions between VH4011499 and representative drugs containing inhibitors and inducers, selected transporters, and statins, in HIV negative adults. The study will also assess to assess safety and tolerability during co-administration of VH4011499 with the selected drugs.
Conditions
- HIV Infections
Interventions
VH4011499Drug
VH4011499 is administered to the participants based on the protocol schedule.
RitonavirDrug
Ritonavir is administered to the participants based on the protocol schedule.
EfavirenzDrug
Efavirenz is administered to the participants based on the protocol schedule.
CarbamazepineDrug
Carbamazepine is administered to the participants based on the protocol schedule.
MetforminDrug
Metformin is administered to the participants based on the protocol schedule.
DigoxinDrug
Digoxin is administered to the participants based on the protocol schedule.
RosuvastatinDrug
Rosuvastatin is administered to the participants based on the protocol schedule.
PitavastatinDrug
Pitavastatin is administered to the participants based on the protocol schedule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum plasma concentration (Cmax) of VH4011499 when administered aloneTime frame: Day 1 for Cohorts 1, 2 and 3
- Cmax of VH4011499 when co-administered with RitonavirTime frame: Day 26
- Cmax of VH4011499 when co-administered with EfavirenzTime frame: Day 37
- Cmax of VH4011499 when co-administered with CarbamazepineTime frame: Day 41
- Area under the concentration-time curve from 0 to tau [AUC(0-t)] of VH4011499 when administered aloneTime frame: Day 1 for Cohorts 1, 2 and 3
- AUC(0-t) of VH4011499 when co-administered with RitonavirTime frame: Day 26
- AUC(0-t) of VH4011499 when co-administered with EfavirenzTime frame: Day 37
- AUC(0-t) of VH4011499 when co-administered with CarbamazepineTime frame: Day 41
- Area under the concentration-time curve from 0 to infinity [AUC(0-inf)] of VH4011499 when administered aloneTime frame: Day 1 for Cohorts 1, 2 and 3
- AUC(0-inf) of VH4011499 when co-administered with RitonavirTime frame: Day 26
- AUC(0-inf) of VH4011499 when co-administered with EfavirenzTime frame: Day 37
- AUC(0-inf) of VH4011499 when co-administered with CarbamazepineTime frame: Day 41
- Cmax of Metformin when administered aloneTime frame: Day 1
- Cmax of Metformin when co-administered with VH4011499Time frame: Day 16
- AUC(0-t) of Metformin when administered aloneTime frame: Day 1
- AUC(0-t) of Metformin when co-administered with VH4011499Time frame: Day 16
- AUC(0-inf) of Metformin when administered aloneTime frame: Day 1
- AUC(0-inf) of Metformin when co-administered with VH4011499Time frame: Day 16
- Cmax of Digoxin when administered aloneTime frame: Day 1
- Cmax of Digoxin when co-administered with VH4011499Time frame: Day 16
- AUC(0-t) of Digoxin when administered aloneTime frame: Day 1
- AUC(0-t) of Digoxin when co-administered with VH4011499Time frame: Day 16
- AUC(0-inf) of Digoxin when administered aloneTime frame: Day 1
- AUC(0-inf) of Digoxin when co-administered with VH4011499Time frame: Day 16
- Cmax of Rosuvastatin when administered aloneTime frame: Day 5
- Cmax of Rosuvastatin when co-administered with VH4011499Time frame: Day 22
- AUC(0-t) of Rosuvastatin when administered aloneTime frame: Day 5
- AUC(0-t) of Rosuvastatin when co-administered with VH4011499Time frame: Day 22
- AUC(0-inf) of Rosuvastatin when administered aloneTime frame: Day 5
- AUC(0-inf) of Rosuvastatin when co-administered with VH4011499Time frame: Day 22
- Cmax of Pitavastatin when administered aloneTime frame: Day 1
- Cmax of Pitavastatin when co-administered with VH4011499Time frame: Day 17
- AUC(0-t) of Pitavastatin when administered aloneTime frame: Day 1
- AUC(0-t) of Pitavastatin when co-administered with VH4011499Time frame: Day 17
- AUC(0-inf) of Pitavastatin when administered aloneTime frame: Day 1
- AUC(0-inf) of Pitavastatin when co-administered with VH4011499Time frame: Day 17
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.